Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline
| العنوان: | Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline |
|---|---|
| المؤلفون: | Howard Jack West, Mark R. Somerfield, Sara Whitlock, Natasha B. Leighl, Suresh S. Ramalingam, Mari Mino-Kenudson, Natasha Rekhtman, William A. Biermann, James N. Huang |
| المصدر: | Journal of Clinical Oncology. 32:3673-3679 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Medical Oncology, Polymerase Chain Reaction, Internal medicine, medicine, Humans, Anaplastic lymphoma kinase, Anaplastic Lymphoma Kinase, Genetic Testing, Epidermal growth factor receptor, Lung cancer, In Situ Hybridization, Fluorescence, Gynecology, Clinical Oncology, Pathology, Clinical, Content area, biology, Molecular pathology, business.industry, Receptor Protein-Tyrosine Kinases, Guideline, medicine.disease, Immunohistochemistry, ErbB Receptors, Mutation, Practice Guidelines as Topic, ASCO Special Articles, biology.protein, business, Tyrosine kinase |
| الوصف: | Purpose The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) guideline on molecular testing for the selection of patients with lung cancer for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors was considered for endorsement. Methods American Society of Clinical Oncology (ASCO) staff reviewed the CAP/IASLC/AMP guideline for developmental rigor; an ASCO ad hoc review panel of experts reviewed the guideline content. Results The ASCO panel concurred that the recommendations are clear, thorough, and based on the most relevant scientific evidence in this content area and present options that will be acceptable to patients. The CAP/IASLC/AMP guideline comprises 37 recommendations (evidence grade A or B), expert consensus opinions, or suggestions that address the following five principal questions: (1) When should molecular testing be performed? (2) How should EGFR testing be performed? (3) How should ALK testing be performed? (4) Should other genes be routinely tested in lung adenocarcinoma? (5) How should molecular testing be implemented and operationalized? Conclusion The ASCO review panel endorses the CAP/IASLC/AMP guideline. This guideline represents an important advance toward standardization of EGFR and ALK testing practices and is of major clinical relevance in advancing the care of patients with lung cancer. In the Discussion section, the ASCO review panel highlights three evolving areas: advances in ALK testing methodology, considerations for selecting appropriate populations for molecular testing, and emergence of other targetable molecular alterations. |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1675d1eda03f8790d927a1481242cd7cTest https://doi.org/10.1200/jco.2014.57.3055Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1675d1eda03f8790d927a1481242cd7c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|